-
2023Hemostasis defects underlying the hemorrhagic syndrome caused by Mammarenaviruses in a cynomolgus macaque model., Blood 2023 Sep; (): .
-
2023Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys., Nat Commun 2023 Mar; 14(1): 1352.
-
2023A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates., Nat Microbiol 2023 Jan; 8(1): 64-76.
-
2022Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys., Virulence 2022 12; 13(1): 654-669.
-
2021A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains., Sci Transl Med 2021 Jun; 13(597): .
-
2021Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques., Commun Biol 2021 Jan; 4(1): 27.
-
2020Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus., Emerg Microbes Infect 2020 Dec; 9(1): 1761-1770.
-
2020Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials., CPT Pharmacometrics Syst Pharmacol 2020 May; 9(5): 258-271.
-
2020Rational design of universal immunotherapy for TfR1-tropic arenaviruses., Nat Commun 2020 01; 11(1): 67.
-
2019A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk., 2019 Dec; 6(12): ofz482.
-
2019Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot., Sci Transl Med 2019 10; 11(512): .
-
2019Fatal Case of Lassa Fever, Bangolo District, Côte d’Ivoire, 2015, Emerging Infect. Dis. 2019 Sep;25(9):1753-1756.
-
2019Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses, Viruses 2019 03;11(3).
-
2019Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus, Viruses 2019 03;11(3).
-
2019Immune parameters and outcomes during Ebola virus disease, JCI Insight 2019 Jan;4(1).
-
2018Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells., PLoS Pathog 2018 Nov; 14(11): e1007430.
-
2018Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies, Nat Commun 2018 10;9(1):4013.
-
2018A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins, J. Virol. 2018 06;92(12).
-
2017Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs, PLoS Pathog. 2017 09;13(9):e1006610.
-
2017Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea, Clin. Infect. Dis. 2017 Jun;64(12):1788-1790.
-
2017Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea, JCI Insight 2017 03;2(6):e88864.
-
2017Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis 2017 02;11(2):e0005389.
-
2017Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study, Lancet Infect Dis 2017 05;17(5):545-552.
-
2016Ocular Complications in Survivors of the Ebola Outbreak in Guinea, Am. J. Ophthalmol. 2017 Mar;175:114-121.
-
2016Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies, N. Engl. J. Med. 2016 12;375(23):2307-2309.
-
2016New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors, J. Infect. Dis. 2016 11;214(10):1475-1476.
-
2016Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med. 2016 Apr;13(4):e1002009.
-
2016Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med. 2016 Mar;13(3):e1001967.
-
2016Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N. Engl. J. Med. 2016 Jan;374(1):33-42.
-
2015[Viral zoonoses and emergence: research is just starting], Med Sci (Paris) 2015 Dec;31(12):1055-6.
-
2015Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement, Clin. Infect. Dis. 2015 Nov;61(10):1627-8.
-
2015Towards deep insight into Ebola virus disease, Lancet Infect Dis 2015 Sep;15(9):991-992.
-
2015Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus, Curr Opin Virol 2015 Feb;10:70-6.
-
2015Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014, J. Clin. Virol. 2015 Jan;62:124-34.
-
2014Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014, Viruses 2014 Nov;6(11):4760-99.
-
2014Ebola: should we consider influenza vaccination?, Lancet 2014 Dec;384(9959):2023-4.
-
2014Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response, J. Virol. 2014 Dec;88(23):13923-7.
-
2014The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses, J. Virol. 2014 Dec;88(23):13811-20.
-
2014Emergence of Zaire Ebola virus disease in Guinea, N. Engl. J. Med. 2014 Oct;371(15):1418-25.
-
2014Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever, PLoS Negl Trop Dis 2014;8(1):e2637.
-
2012Immune responses and Lassa virus infection, Viruses 2012 Nov;4(11):2766-85.
-
2012NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression, Eur. J. Immunol. 2012 Jul;42(7):1822-32.
-
2011Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages, J. Virol. 2011 Nov;85(22):12093-7.
-
2011Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus, J. Virol. 2011 Aug;85(16):8293-306.
-
2011Evidence for Ebola virus superantigen activity, J. Virol. 2011 Apr;85(8):4041-2.
-
2010Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis, PLoS Negl Trop Dis 2010 Oct;4(10).
-
2010Towards broad protection against Ebolaviruses, Future Microbiol 2010 Oct;5(10):1469-73.
-
2009Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys, J. Virol. 2009 Jun;83(11):5890-903.
-
2006Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages, Microbes Infect. 2006 Apr;8(5):1194-202.
-
2005A single shot against Ebola and Marburg virus, Nat. Med. 2005 Jul;11(7):720-1.
-
2004Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection, J. Virol. 2004 Oct;78(19):10516-24.
-
2004Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells, J. Immunol. 2004 Mar;172(5):2861-9.
-
2003[Ebola hemorrhagic fever: a unique efficacious vaccine dose in primates], Med Sci (Paris) 2003 Dec;19(12):1183-4.